Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LISAH: Subcutaneous trastuzumab injected into thigh vs upper arm in HER2-positive early breast cancer
2013-001023-39Phase 2Suspended
- Sponsor
- Roche
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Quality of life associated with injection site (thigh vs upper arm). Started Jul 2013; status: suspended.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001023-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001023-39.